Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology.
PubMed 16919519 · doi:10.1016/j.amjcard.2005.12.029
What was done
The author reviewed the pharmacological and clinical profile of Omacor (omega-3-acid ethyl esters), a prescription formulation containing 465 mg eicosapentaenoic acid (EPA), 375 mg docosahexaenoic acid (DHA), and 4 mg vitamin E per 1-g capsule. The review evaluated its lipid effects at a dose of 4 capsules/day (monotherapy or combined with statins or fibrates) and its safety and tolerability profile.
What was found
The abstract reports no numerical effect sizes or statistical values. It states that Omacor at 4 capsules/day significantly lowers plasma triglyceride levels alone or in combination with statins or fibrates, modestly increases low-density lipoprotein cholesterol, increases high-density lipoprotein cholesterol, and favorably affects lipoprotein particle size and subclass distribution. Adverse effects were reported as mild gastrointestinal symptoms, with no reported hyperglycemia, abnormal bleeding, muscle/liver enzyme elevations, or renal/neurologic toxicity.
Why it matters
It summarizes the lipid-modifying efficacy, safety, and tolerability profile of a concentrated prescription omega-3 fatty acid formulation for hypertriglyceridemia management.
Limits
As a narrative review, it lacks a systematic search protocol, quality appraisal of cited trials, and pooled quantitative analyses. The abstract reports no sample sizes, baseline lipid values, quantitative effect magnitudes, or clinical cardiovascular endpoint data.
Cited by
- context Lovaza contains EPA and DHA in an approximate ratio of 2:1 to 3:2.